YOCON latest FaCHiP has passed CE certification!

Yocon Market


Company Events

On September 16, 2021, FaCHiP COVID-19 Antigen Test Kit (Colloidal Gold) newly developed by YOCON successfully passed the laboratory test and received the CE marking (registration number NL-CA002-2021-62077) uniformly recognized by the EU authorities, and was included in the white list of the Chinese Chamber of Commerce for Import and Export of Medicines and Health Products.

CE marking proves that our products are safe and in full compliance with specifications, providing professional and excellent guarantee for safety and quality indexes of our products. It also represents our determination to expand the trade market and enhance the strategic planning of international import and export business.


FaCHiP COVID-19 Antigen Test Kit (Colloidal Gold) is designed to shorten the testing time and provide fast testing results within 15 minutes to facilitate the self-test by individuals and families, and better meet the needs of rapid testing for epidemic prevention and control. YOCON Biology will continue to contribute to the epidemic response in countries around the world.


On the basis of more than 10 years of stable development in molecular diagnosis field, its products are mainly used for sample collection, extraction and testing in CDCs, hospitals, customs, etc. After the outbreak of COVID-19, YOCON virus sampling products are available as rare products registered under Class II medical devices in China. The company has become one of the key government-appointed enterprises for epidemic prevention and control.

In response to the COVID-19 outbreak, YOCON has been contributing to the virus detection. In the current context of severe epidemic situation, YOCON Biology, as a national enterprise, will make every effort to provide high-quality molecular diagnostic products on the basis of sense of social responsibility, and will continue to insist on independent R&D, refine our products and serve our customers with craftsmanship, in order to contribute to the R&D of life science and biomedicine, and continuously drive the epidemic prevention and control in countries around the world.